Physician profile
Steven Anthony Monte
NPI 1104850056
$849.48
in general payments reported to CMS, 2019-2025
14 companies · $52.13 in 2025
The $52.13 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $114 · 2021: $20.83 · 2025: $52.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $200.95 | 2019-2020 | |
| Celgene Corporation | $175.19 | 2019-2020 | |
| Eisai INC. | $94.56 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $65.12 | 2019 | |
| Puma Biotechnology, INC. | $62.88 | 2019 | |
| Janssen Biotech, INC. | $51.22 | 2019 | |
| Jazz Pharmaceuticals INC. | $48.88 | 2019-2020 | |
| Stemline Therapeutics INC. | $31.80 | 2019-2020 | |
| Madrigal Pharmaceuticals | $29.84 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $22.29 | 2025 | Vyloy |
| Siemens Medical Solutions USA, INC. | $20.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.13 | 2019 | |
| Seagen INC. | $14.37 | 2019 | |
| Aurobindo Pharma USA, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Monte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.